These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 16631330)

  • 1. Predictive factors of treatment interruption duration in a cohort of HIV-1 infected patients with CD4 count greater than 350 cells per mm3.
    Fillaux J; Delpierre C; Alvarez M; Jaafar A; Marchou B; Massip P; Cuzin L
    Med Mal Infect; 2006 Jun; 36(6):335-9. PubMed ID: 16631330
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interruption of antiretroviral treatment in HIV-infected patients with preserved immune function is associated with a low rate of clinical progression: a prospective study by AIDS Clinical Trials Group 5170.
    Skiest DJ; Su Z; Havlir DV; Robertson KR; Coombs RW; Cain P; Peterson T; Krambrink A; Jahed N; McMahon D; Margolis DM;
    J Infect Dis; 2007 May; 195(10):1426-36. PubMed ID: 17436222
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment interruption of highly active antiretroviral therapy in patients with nadir CD4 cell counts >200 cells/mm3.
    Toulson AR; Harrigan R; Heath K; Yip B; Brumme ZL; Harris M; Hogg RS; Montaner JS
    J Infect Dis; 2005 Nov; 192(10):1787-93. PubMed ID: 16235178
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A high HIV DNA level in PBMCs at antiretroviral treatment interruption predicts a shorter time to treatment resumption, independently of the CD4 nadir.
    Piketty C; Weiss L; Assoumou L; Burgard M; Mélard A; Ragnaud JM; Bentata M; Girard PM; Rouzioux C; Costagliola D;
    J Med Virol; 2010 Nov; 82(11):1819-28. PubMed ID: 20872707
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and factors predicting the duration of first and second treatment interruptions guided by CD4+ cell counts in patients with chronic HIV infection.
    Boschi A; Tinelli C; Ortolani P; Arlotti M
    J Antimicrob Chemother; 2006 Mar; 57(3):520-6. PubMed ID: 16387747
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extended antiretroviral treatment interruption in HIV-infected patients with long-term suppression of plasma HIV RNA.
    Achenbach CJ; Till M; Palella FJ; Knoll MD; Terp SM; Kalnins AU; Murphy RL
    HIV Med; 2005 Jan; 6(1):7-12. PubMed ID: 15670246
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD4 cell-monitored treatment interruption in patients with a CD4 cell count > 500 x 106 cells/l.
    Mussini C; Bedini A; Borghi V; Guaraldi G; Esposito R; Barchi E; Enilia R; Cozzi-Lepri A; Philips AN; Ortolani P; Bratt G; Eriksson LE; Sighinolfi L; Cossarizza A; d'Arminio Monforte A; De Luca A; Di Giambenedetto S; Antinori A;
    AIDS; 2005 Feb; 19(3):287-94. PubMed ID: 15718839
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interruption of combination antiretroviral therapy and risk of clinical disease progression to AIDS or death.
    Holkmann Olsen C; Mocroft A; Kirk O; Vella S; Blaxhult A; Clumeck N; Fisher M; Katlama C; Phillips AN; Lundgren JD;
    HIV Med; 2007 Mar; 8(2):96-104. PubMed ID: 17352766
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive factors for immunological and virological endpoints in Thai patients receiving combination antiretroviral treatment.
    Srasuebkul P; Ungsedhapand C; Ruxrungtham K; Boyd MA; Phanuphak P; Cooper DA; Law MG
    HIV Med; 2007 Jan; 8(1):46-54. PubMed ID: 17305932
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prolonged treatment interruption after immunologic response to highly active antiretroviral therapy.
    Tarwater PM; Parish M; Gallant JE
    Clin Infect Dis; 2003 Dec; 37(11):1541-8. PubMed ID: 14614678
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD4 cell count and HIV DNA level are independent predictors of disease progression after primary HIV type 1 infection in untreated patients.
    Goujard C; Bonarek M; Meyer L; Bonnet F; Chaix ML; Deveau C; Sinet M; Galimand J; Delfraissy JF; Venet A; Rouzioux C; Morlat P;
    Clin Infect Dis; 2006 Mar; 42(5):709-15. PubMed ID: 16447119
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictive value of immune parameters before treatment interruption (TI) for CD4+ T-cell count change during TI in HIV infection.
    Huang KH; Loutfy MR; Boulet S; Toma E; Tsoukas CM; Bernard NF
    Antivir Ther; 2009; 14(3):381-92. PubMed ID: 19474472
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy.
    Steingrover R; Pogány K; Fernandez Garcia E; Jurriaans S; Brinkman K; Schuitemaker H; Miedema F; Lange JM; Prins JM
    AIDS; 2008 Aug; 22(13):1583-8. PubMed ID: 18670217
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiretroviral therapy interruption guided by CD4 cell counts and plasma HIV-1 RNA levels in chronically HIV-1-infected patients.
    Ruiz L; Paredes R; Gómez G; Romeu J; Domingo P; Pérez-Alvarez N; Tambussi G; Llibre JM; Martínez-Picado J; Vidal F; Fumaz CR; Clotet B;
    AIDS; 2007 Jan; 21(2):169-78. PubMed ID: 17197807
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD4+ T cell count recovery in HIV type 1-infected patients is independent of class of antiretroviral therapy.
    Khanna N; Opravil M; Furrer H; Cavassini M; Vernazza P; Bernasconi E; Weber R; Hirschel B; Battegay M; Kaufmann GR;
    Clin Infect Dis; 2008 Oct; 47(8):1093-101. PubMed ID: 18783328
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro cytopathogenicity of the human immunodeficiency virus (HIV)-1 predicts survival in HIV-infected hemophiliacs independent from CD4 cell count.
    Rockstroh JK; Woitas RP; Brackmann HH; Kupfer B; Kaiser R; Schneweis KE; Sudhop T; Spengler U
    Eur J Med Res; 1998 May; 3(5):223-30. PubMed ID: 9580568
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunophenotype of HIV+ patients during CD4 cell-monitored treatment interruption: role of the IL-7/IL-7 receptor system.
    Nemes E; Lugli E; Nasi M; Ferraresi R; Pinti M; Bugarini R; Borghi V; Prati F; Esposito R; Cossarizza A; Mussini C
    AIDS; 2006 Oct; 20(16):2021-32. PubMed ID: 17053348
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors of virological outcome and safety in primary HIV type 1-infected patients initiating quadruple antiretroviral therapy: QUEST GW PROB3005.
    Hoen B; Cooper DA; Lampe FC; Perrin L; Clumeck N; Phillips AN; Goh LE; Lindback S; Sereni D; Gazzard B; Montaner J; Stellbrink HJ; Lazzarin A; Ponscarme D; Staszewski S; Mathiesen L; Smith D; Finlayson R; Weber R; Wegmann L; Janossy G; Kinloch-de Loes S;
    Clin Infect Dis; 2007 Aug; 45(3):381-90. PubMed ID: 17599319
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD4+ T-cell count increase in HIV-1-infected patients with suppressed viral load within 1 year after start of antiretroviral therapy.
    Wolbers M; Battegay M; Hirschel B; Furrer H; Cavassini M; Hasse B; Vernazza PL; Bernasconi E; Kaufmann G; Bucher HC;
    Antivir Ther; 2007; 12(6):889-97. PubMed ID: 17926643
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factors predicting the time for CD4 T-cell count to return to nadir in the course of CD4-guided therapy interruption in chronic HIV infection.
    Boschi A; Tinelli C; Ortolani P; Arlotti M
    HIV Med; 2008 Jan; 9(1):19-26. PubMed ID: 18199169
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.